EIGER BIOPHARMACEUTICALS INC's ticker is EIGR and the CUSIP is 28249U105. A total of 57 filers reported holding EIGER BIOPHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $82,134 | -62.3% | 269,293 | -13.1% | 0.00% | – |
| Q2 2023 | $218,100 | +1817400.0% | 309,801 | +2143.6% | 0.00% | – |
| Q1 2023 | $12 | -98.7% | 13,808 | -98.2% | 0.00% | -100.0% |
| Q4 2022 | $905 | -99.2% | 767,121 | +4328.8% | 0.00% | – |
| Q3 2021 | $116,000 | -90.3% | 17,321 | -87.2% | 0.00% | -100.0% |
| Q1 2021 | $1,194,000 | -36.7% | 134,865 | -12.2% | 0.00% | 0.0% |
| Q4 2020 | $1,887,000 | +2044.3% | 153,542 | +1092.3% | 0.00% | – |
| Q1 2020 | $88,000 | -74.0% | 12,878 | -43.3% | 0.00% | – |
| Q4 2019 | $339,000 | -88.6% | 22,721 | -89.3% | 0.00% | -100.0% |
| Q1 2019 | $2,970,000 | +1064.7% | 212,430 | +747.3% | 0.00% | – |
| Q4 2018 | $255,000 | -70.7% | 25,072 | -64.9% | 0.00% | -100.0% |
| Q2 2018 | $871,000 | +67.5% | 71,371 | +91.5% | 0.00% | 0.0% |
| Q4 2017 | $520,000 | -5.5% | 37,265 | -25.5% | 0.00% | 0.0% |
| Q3 2017 | $550,000 | +50.7% | 49,997 | +8.1% | 0.00% | 0.0% |
| Q2 2017 | $365,000 | – | 46,234 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| P.A.W. CAPITAL CORP | 540,000 | $4,482,000 | 4.68% |
| Knoll Capital Management, LLC | 694,232 | $5,762,000 | 3.62% |
| Telemetry Investments, L.L.C. | 213,000 | $1,768,000 | 2.79% |
| ACT CAPITAL MANAGEMENT, LLC | 250,000 | $2,075,000 | 2.20% |
| VR Adviser, LLC | 1,469,767 | $12,199,000 | 1.98% |
| INTERWEST VENTURE MANAGEMENT CO | 560,990 | $4,656,000 | 1.78% |
| 683 Capital Management, LLC | 3,375,000 | $28,013,000 | 1.50% |
| Trellus Management Company, LLC | 300,000 | $2,490,000 | 1.45% |
| Altium Capital Management LP | 440,000 | $3,652,000 | 1.22% |
| CAXTON CORP | 116,884 | $970,000 | 1.21% |